Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-50
SponsorChangchun BCHT Biotechnology Co.

About this trial

To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people

Eligibility criteria

Qualifiers

Before the trial, I have had a detailed understanding of the nature, significance and possible benefits of the trial, the possible inconvenience and potential risks and discomfort, and volunteered to participate in this clinical trial, was able to communicate well with researchers, comply with the requirements of the whole study, and signed a written informed consent;

Men or women aged 18~50 (including boundary values) at the time of screening;

The weight of female volunteers was 45.0 kg and 80.0 kg, that of male volunteers was 50.0 kg and 80.0 kg, and the body mass index (BMI) was between 18.0 and 27.0 kg/m2 (including boundary value) (BMI= weight kg / height m2);

Female volunteers have no fertility or egg donation plan within 14 days before the first dose to 3 months after the end of the trial and voluntarily take effective physical contraception, while male volunteers have no fertility or sperm donation plan within 3 months after the first dose to the trial and voluntarily take effective physical contraception.

Disqualifiers

Those who are known to be allergic to the study drug (including excipients, similar drugs), or suffer from severe allergic diseases or allergic constitution (such as allergic to two or more drugs, food or pollen), may damage the safety of the volunteers in the judgment of the investigator (inquiry);

Those with a clear history of allergy to the essential substances (such as skin disinfectants) that may be exposed to during the test (inquiry);

Patients with a history of clinically serious disease within 6 months (180 days) before the first dose and not cured, or patients with acute or chronic diseases that may significantly affect the in vivo process or safety evaluation of the study drug (inquiry);

Patients with a previous history of autoimmune diseases or chronic hepatitis (inquiry);

Trial design

Treatments tested in this trial

  • Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg
  • Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg
  • Rabies Human Immunoglobulin (HRIG)
  • Lyophilized rabies vaccine for human use (Vero cells)

Treatment groups

120 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Changchun BCHT Biotechnology Co.

Lead sponsor

The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine

Collaborator

Anning City First People's Hospital

Collaborator

Yunnan Central Hospital

Collaborator

Beijing Contreke Statistical Technology Co., LTD

Collaborator

Military Science Zhengyuan (Beijing) Pharmaceutical Research Co., LTD

Collaborator